95 related articles for article (PubMed ID: 28855436)
1. Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells.
Sawa A; Chiba T; Ishii J; Yamamoto H; Hara H; Kamma H
Endocr J; 2017 Nov; 64(11):1115-1123. PubMed ID: 28855436
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
3. Growth suppression of thyroid cancer cells by adenylcyclase activator.
Yano Y; Kamma H; Matsumoto H; Fujiwara M; Bando H; Hara H; Yashiro T; Ueno E; Ito K; Uchida K
Oncol Rep; 2007 Aug; 18(2):441-5. PubMed ID: 17611668
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor.
Ohta K; Pang XP; Berg L; Hershman JM
J Clin Endocrinol Metab; 1997 Aug; 82(8):2633-8. PubMed ID: 9253346
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
6. The adenylyl cyclase-cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF-kappaB in HaCaT keratinocytes.
Qi XF; Kim DH; Yoon YS; Li JH; Song SB; Jin D; Huang XZ; Teng YC; Lee KJ
Mol Immunol; 2009 Jun; 46(10):1925-34. PubMed ID: 19371952
[TBL] [Abstract][Full Text] [Related]
7. Mutual antagonistic interactions between the thyrotropin (adenosine 3',5'-monophosphate) and protein kinase C/epidermal growth factor (tyrosine kinase) pathways in cell proliferation and differentiation of cultured human thyroid follicles.
Kraiem Z; Sadeh O; Yosef M; Aharon A
Endocrinology; 1995 Feb; 136(2):585-90. PubMed ID: 7835292
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer.
Yi H; Ye T; Ge M; Yang M; Zhang L; Jin S; Ye X; Long B; Li L
Oncol Rep; 2018 Feb; 39(2):711-720. PubMed ID: 29207150
[TBL] [Abstract][Full Text] [Related]
10. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
11. PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest.
Datta NS; Chen C; Berry JE; McCauley LK
J Bone Miner Res; 2005 Jun; 20(6):1051-64. PubMed ID: 15883646
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase.
Tamir A; Granot Y; Isakov N
J Immunol; 1996 Aug; 157(4):1514-22. PubMed ID: 8759733
[TBL] [Abstract][Full Text] [Related]
13. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation.
D'Angelo G; Lee H; Weiner RI
J Cell Biochem; 1997 Dec; 67(3):353-66. PubMed ID: 9361190
[TBL] [Abstract][Full Text] [Related]
14. Progesterone secretion by luteinizing human granulosa cells: a possible cAMP-dependent but PKA-independent mechanism involved in its regulation.
Chin EC; Abayasekara DR
J Endocrinol; 2004 Oct; 183(1):51-60. PubMed ID: 15525573
[TBL] [Abstract][Full Text] [Related]
15. Adenylyl cyclase-cAMP system inhibits thyroid hormone-stimulated osteocalcin synthesis in osteoblasts.
Kanno Y; Ishisaki A; Yoshida M; Nakajima K; Tokuda H; Numata O; Kozawa O
Mol Cell Endocrinol; 2005 Jan; 229(1-2):75-82. PubMed ID: 15607531
[TBL] [Abstract][Full Text] [Related]
16. Adenylyl cyclase 3/adenylyl cyclase-associated protein 1 (CAP1) complex mediates the anti-migratory effect of forskolin in pancreatic cancer cells.
Quinn SN; Graves SH; Dains-McGahee C; Friedman EM; Hassan H; Witkowski P; Sabbatini ME
Mol Carcinog; 2017 Apr; 56(4):1344-1360. PubMed ID: 27891679
[TBL] [Abstract][Full Text] [Related]
17. Growth factor-induced transcription via the serum response element is inhibited by cyclic adenosine 3',5'-monophosphate in MCF-7 breast cancer cells.
Lowe WL; Fu R; Banko M
Endocrinology; 1997 Jun; 138(6):2219-26. PubMed ID: 9165004
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
19. The role of cAMP-MAPK signalling in the regulation of human hepatocellular carcinoma growth in vitro.
Schmidt CM; McKillop IH; Cahill PA; Sitzmann JV
Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1393-9. PubMed ID: 10654800
[TBL] [Abstract][Full Text] [Related]
20. Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
Zhang YN; Wu XY; Zhong N; Deng J; Zhang L; Chen W; Li X; Zhong CJ
Mol Med Rep; 2014 Jan; 9(1):365-9. PubMed ID: 24213303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
